日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

Corrigendum to Bimekizumab treatment in biologic DMARD-naïve patients with active psoriatic arthritis: 52-week efficacy and safety results from the phase III, randomised, placebo-controlled, active reference BE OPTIMAL study Ann Rheum Dis. 2023;82:1404-1414

关于在未接受过生物制剂DMARD治疗的活动性银屑病关节炎患者中应用Bimekizumab治疗的更正：来自III期随机、安慰剂对照、活性参考BE OPTIMAL研究的52周疗效和安全性结果 Ann Rheum Dis. 2023;82:1404-1414

期刊:Annals of the Rheumatic Diseases
影响因子:20.6
doi:10.1016/j.ard.2025.05.013
Ritchlin, Christopher T; Coates, Laura C; McInnes, Iain B; Mease, Philip J; Merola, Joseph F; Tanaka, Yoshiya; Asahina, Akihiko; Gossec, Laure; Gottlieb, Alice B; Warren, Richard B; Ink, Barbara; Bajracharya, Rajan; Shende, Vishvesh; Coarse, Jason; Landewé, Robert B M
关节炎
银屑病
TIM
发表日期：2026
文献求助 收藏

Bimekizumab longer-term safety profile in adult patients with axial spondyloarthritis or psoriatic arthritis: an updated analysis of six phase IIb/III clinical studies

Bimekizumab 在成人中轴型脊柱关节炎或银屑病关节炎患者中的长期安全性：六项 IIb/III 期临床研究的最新分析

期刊:RMD Open
影响因子:4.7
doi:10.1136/rmdopen-2025-006174
Mease, Philip J; Merola, Joseph F; Magrey, Marina; Nash, Peter; Poddubnyy, Denis; Lebwohl, Mark; Bajracharya, Rajan; Ink, Barbara; Marten, Alexander; Manente, Myriam; Peterson, Luke; White, Katy; Gensler, Lianne S
关节炎
银屑病
发表日期：2026
文献求助 收藏

Bimekizumab Efficacy and Safety in Patients with Psoriatic Arthritis with Substantial Skin and Nail Psoriasis to 1 Year

比美珠单抗治疗伴有严重皮肤和指甲银屑病的银屑病关节炎患者的疗效和安全性（长达 1 年）

期刊:Dermatology and Therapy
影响因子:4.2
doi:10.1007/s13555-025-01599-5
Thaçi, Diamant; Asahina, Akihiko; Boehncke, Wolf-Henning; Gottlieb, Alice B; Lebwohl, Mark; Warren, Richard B; Edens, Heather; Ink, Barbara; Bajracharya, Rajan; Coarse, Jason; Merola, Joseph F
关节炎
银屑病
发表日期：2026
文献求助 收藏

Sustained improvements in health status and work productivity with bimekizumab in psoriatic arthritis: 2-year results from two phase 3 studies

比美珠单抗治疗银屑病关节炎可持续改善患者的健康状况和工作效率：两项 3 期研究的 2 年结果

期刊:Rheumatology Advances in Practice
影响因子:2.1
doi:10.1093/rap/rkag009
Tillett, William; Gossec, Laure; Husni, M Elaine; Morita, Akimichi; Ink, Barbara; Bajracharya, Rajan; Healy, Patrick; Mørup, Michael F; Walsh, Jessica A
关节炎
银屑病
发表日期：2026
文献求助 收藏

Long-term safety of bimekizumab in adult patients with axial spondyloarthritis or psoriatic arthritis: pooled results from integrated phase IIb/III clinical studies

比美珠单抗治疗成人中轴型脊柱关节炎或银屑病关节炎的长期安全性：来自IIb/III期综合临床研究的汇总结果

期刊:RMD Open
影响因子:4.7
doi:10.1136/rmdopen-2024-005026
Mease, Philip J; Gensler, Lianne S; Orbai, Ana-Maria; Warren, Richard B; Bajracharya, Rajan; Ink, Barbara; Marten, Alexander; Massow, Ute; Shende, Vishvesh; Manente, Myriam; Peterson, Luke; White, Katy; Landewé, Robert; Poddubnyy, Denis
关节炎
银屑病
发表日期：2025
文献求助 收藏

Correction: Safety and Efficacy of Bimekizumab in Patients with Psoriatic Arthritis: 2-Year Results from Two Phase 3 Studies

更正：比美珠单抗治疗银屑病关节炎患者的安全性和有效性：两项3期研究的2年结果

期刊:Rheumatology and Therapy
影响因子:2.9
doi:10.1007/s40744-025-00761-x
Mease, Philip J; Merola, Joseph F; Tanaka, Yoshiya; Gossec, Laure; McInnes, Iain B; Ritchlin, Christopher T; Landewé, Robert B M; Asahina, Akihiko; Ink, Barbara; Heinrichs, Andrea; Bajracharya, Rajan; Shende, Vishvesh; Coarse, Jason; Coates, Laura C
关节炎
银屑病
发表日期：2025
文献求助 收藏

Summary of Research: Safety and Efficacy of Bimekizumab in Patients with Psoriatic Arthritis: 2-Year Results from Two Phase 3 Studies

研究总结：比美珠单抗治疗银屑病关节炎患者的安全性和有效性：两项3期研究的2年结果

期刊:Rheumatology and Therapy
影响因子:2.9
doi:10.1007/s40744-025-00764-8
Mease, Philip J; Merola, Joseph F; Tanaka, Yoshiya; Gossec, Laure; McInnes, Iain B; Ritchlin, Christopher T; Landewé, Robert B M; Asahina, Akihiko; Ink, Barbara; Heinrichs, Andrea; Bajracharya, Rajan; Shende, Vishvesh; Coarse, Jason; Coates, Laura C
关节炎
银屑病
发表日期：2025
文献求助 收藏

Validity and score interpretation of the 12-item Psoriatic Arthritis Impact of Disease: an analysis of pooled data from two phase 3 trials of bimekizumab in patients with psoriatic arthritis

12项银屑病关节炎疾病影响量表的有效性和评分解释：对两项bimekizumab治疗银屑病关节炎患者的3期临床试验汇总数据的分析

期刊:RMD Open
影响因子:4.7
doi:10.1136/rmdopen-2023-003548
Gossec, Laure; Orbai, Ana-Maria; Coates, Laura C; Gladman, Dafna D; Ogdie, Alexis; Pelligra, Christopher G; Ciaravino, Valérie; Ink, Barbara; Taieb, Vanessa; Lambert, Jérémy; de Wit, Maarten
关节炎
银屑病
发表日期：2024
文献求助 收藏

Bimekizumab treatment in patients with active psoriatic arthritis and prior inadequate response to tumour necrosis factor inhibitors: 52-week safety and efficacy from the phase III BE COMPLETE study and its open-label extension BE VITAL

在既往对肿瘤坏死因子抑制剂反应不足的活动性银屑病关节炎患者中，比美珠单抗治疗的52周安全性和有效性：来自III期BE COMPLETE研究及其开放标签扩展研究BE VITAL的评估

期刊:RMD Open
影响因子:4.7
doi:10.1136/rmdopen-2023-003855
Coates, Laura C; Landewé, Robert; McInnes, Iain B; Mease, Philip J; Ritchlin, Christopher T; Tanaka, Yoshiya; Asahina, Akihiko; Behrens, Frank; Gladman, Dafna D; Gossec, Laure; Orbai, Ana-Maria; Gottlieb, Alice B; Warren, Richard B; Ink, Barbara; Bajracharya, Rajan; Shende, Vishvesh; Coarse, Jason; Merola, Joseph F
肿瘤
肿瘤免疫
银屑病
OMP
COMP
MPL
关节炎
发表日期：2024
文献求助 收藏

Bimekizumab provided rapid improvements in patient-reported symptoms and health-related quality of life in patients with active psoriatic arthritis: pooled 16-week results from two phase 3 studies

汇总两项 3 期研究的 16 周结果显示，Bimekizumab 可迅速改善活动性银屑病关节炎患者的自述症状和健康相关生活质量。

期刊:RMD Open
影响因子:4.7
doi:10.1136/rmdopen-2024-004464
Husni, M Elaine; Mease, Philip J; Merola, Joseph F; Tillett, William; Goldammer, Nadine; Ink, Barbara; Coarse, Jason; Lambert, Jérémy; Taieb, Vanessa; Gladman, Dafna D
关节炎
银屑病
发表日期：2024
文献求助 收藏